Best of the Week
Most Popular
1. Crude Oil and Water: How Climate Change is Threatening our Two Most Precious Commodities - Richard_Mills
2.The Potential $54 Trillion Cost Of The Fed's Planned Interest Rate Increases - Dan_Amerman
3.Best Cash ISA Savings for Rising UK Interest Rates and High Inflation - March 2018 - Nadeem_Walayat
4.Fed Interest Hikes, US Dollar, and Gold - Zeal_LLC
5.What Happens Next after February’s Stock Market Selloff - Troy_Bombardia
6.The 'Beast from the East' UK Extreme Snow Weather - Sheffield Day 2 - N_Walayat
7.Currencies Will Be ‘Flushed Down the Toilet’ Triggering a ‘Mad Rush into Gold’ - MoneyMetals
8.Significant Decline In Stocks On The Cards! -Enda_Glynn
9.Land Rover Discovery Sport Extreme Driving "Beast from the East" Snow Weather Test - N_Walayat
10.SILVER Large Specualtors Net Short Position 15 Year Anniversary - Clive_Maund
Last 7 days
Bitcoin Price Trend Forecast, Paypal FUD Fake Cryptocurrency Warning - 17th Mar 18
Strong Earnings Growth is Bullish for Stocks - 17th Mar 18
The War on the Post Office - 17th Mar 18
GDX Gold Mining Stocks Fundamentals - 16th Mar 18
Nationalism, Not the Russians, got Trump Elected - 16th Mar 18
Has Bitcoin Bought It? - 16th Mar 18
Crude Oil Price – Who Wants the Triangle? - 16th Mar 18
PayPal Cease Trading Crypto Currency Bitcoin Warning Email Sophisticated Fake Scam? - 16th Mar 18
EUR/USD – Something Old, Something New and… Something Blue - 16th Mar 18
DasCoin: A 5-Minute Guide to How It Works - 15th Mar 18
Stock Market Downward Pressure Mounting - 15th Mar 18
The Stock Market Trend is Your Friend ’til the Very End - 15th Mar 18
6 Easy Ways to Get What Women Want, for Less! - 15th Mar 18
This Isn’t Your Grandfather’s (1960s) Inflation Scare - 15th Mar 18
Eye Opening Stock Market Index, Volatility, Charts and Predictions - 15th Mar 18
Gold Cup At Cheltenham – Gold Is For Winners, Not For Gamblers - 15th Mar 18
Upcoming Turnaround in Gold - 14th Mar 18
Will the Stock Market Make Another Correction this Year? - 14th Mar 18
4 Ways To Writing An Interesting Education Research Paper - 14th Mar 18
China Toward Sustainable Economic Growth - 14th Mar 18
Stock Market Direction Is No Longer Important - 14th Mar 18
Trade Tariffs Defeat Globalists and Return Prosperity - 14th Mar 18
Stock Market Crash is Underway and Cannot be Stopped! - 14th Mar 18
Are Energy Sector Stocks Bottoming? - 14th Mar 18
Nasdaq Stocks Soars to New Record High After Strong Job Reports - 14th Mar 18
Bitcoin BTCUSD Elliott Wave View Calling for Rally toward $15,000 - 13th Mar 18
Hungary’s Gold Repatriation Adds To Growing Protest Against US Dollar Hegemony - 13th Mar 18
Record Low Volatility in Precious Metals and What it Means - 13th Mar 18
Tips for Writing and Assembling the Classification Essay - 13th Mar 18
Gerald Celente "If Rates go up too High, the Economy goes Down, End of Story" - 13th Mar 18
Stock Market Selloff Showed Gold Can Reduce Portfolio Risk  - 13th Mar 18
Silver Does it Again! Severe Consequences - 12th Mar 18
Has the Stock Market Rally Run Out of Steam? - 12th Mar 18
S&P 500 at 2,800 Again, Stock Market Breakout or Fakeout? - 12th Mar 18
The No.1 Energy Stock To Buy Right Now - 12th Mar 18
What Happens Next When Stock Market Investor Sentiment is Neutral - 12th Mar 18
Economic Pressures To Driving Gold and Silver Prices Higher Long-Term - 12th Mar 18
Labour Sheffield City Councils Secret Plan to Fell 50% of Street Trees Exposed! - 12th Mar 18
Stock Market Uptrend Resuming? - 11th Mar 18
Bond Market Interest Rate Yields Are Rising Again… Stocks Are on Thin Ice - 11th Mar 18
Death of Europe's Greenest City, Police State Sheffield Labour Council to Fell 50% of Street Trees - 11th Mar 18
Do All Bull Stocks Markets Need to Have a Bearish Divergence? - 11th Mar 18
An Inflation Indicator to Watch, Part 3 - 11th Mar 18
Online Stock Trading Tips - Tips about Online Trading & Day Trading - 11th Mar 18
NDX makes a new high. What does that mean? - 10th Mar 18
Blue Chip Companies on Track for $800 billion Buyback Record in 2018 - 10th Mar 18
Cheap Gold Stocks Basing - 10th Mar 18
An Introduction to Online Forex Trading - 10th Mar 18

Market Oracle FREE Newsletter

Urgent Stock Market Message

The Smart Money Is Piling Into Regenerative Medicine

Companies / BioTech Apr 18, 2017 - 06:12 PM GMT

By: John_Mauldin


BY PATRICK COX : The Congressional Budget Office released its long-term budget outlook. This report should have sparked a national discussion about societal aging, but big media largely ignored it.

Fortunately, there are signs that smart investors are hedging this failure by investing in regenerative medicine (RM).

Over the last few years, the CBO has emerged as one of the few grownups in the room. Its annual budget projections have focused on population aging as the main driver of US federal deficit and the debt.

The core message of "The 2017 Long-Term Budget Outlook" is simple: Mandated transfer payments for our increasingly older demographic are just too much.

These costs have crippled the federal government and the private sector. The CBO warns that this is causing economic instability. As a result, a cascade of financial crises is more and more likely.

Only three parts of the budget are growing in relation to the whole. They are Social Security, health care, and net interest.

Social Security is clearly about the aged, so are increased healthcare costs. The CBO says those costs will continue to rise.

The reason? We are living longer and new treatments for age-related diseases continue to emerge. But even if dramatic cuts are made to benefits for the aged, it will only slow the meltdown.

Why? Long-term demographic trends will continue. Life expectancies will keep rising as birthrates fall.

Progressive Approval Could Be a Game Changer for RM

Japan is ahead of the curve in terms of demographics, but the US will soon get there. It is important to note that Japan has failed to produce political solutions to its budgetary woes.

But Japan has started to look at this problem through a different lens. These economic issues can be solved by addressing aging itself.

Japanese lawmakers have instituted progressive approval for regenerative medicine (RM). That means after successful safety trials, RM therapies can be approved. Data will then be collected and made public.

Critics of progressive approval claim it could legalize ineffective treatments. The Japanese think that the risk of delaying true anti-aging therapies is greater than the risk of approving ineffective treatments.

Japanese leadership seems to have had a major impact on the investment community. Now, US firms are eyeing the prospect of gaining much faster approvals in Japan.

This has major financial implications for RM biotechs.

Investing in Regenerative Medicine

A recent report from Goldman Sachs includes a section titled “The Coming Age of Regenerative Medicine.”

Business Insider article about the report is aptly titled “Money is pouring in to a hot new area of science that could change the way we think about aging.

According to the article, “venture capital in companies pursuing regenerative medicine increased from $296 million in 2011 to $807 million in 2016, growing roughly 34% year-over-year.”

The author also writes that, “by the report's count, 80 regenerative-medicine companies received funding in the last three years, and the deals related to regenerative medicine accounted for almost half of the top venture-capital deals in 2015 and 2016.”

Two years ago, Fed Chair Janet Yellen threw cold water on biotech. She compared it to overheated social media.

I think Yellen was wrong. And her off-the-cuff comment hurt startups struggling to find funds in order to survive.

On the other hand, economist John Mauldin has long predicted that there will be a bubble following the public’s realization of the power of emerging RM.

But bubbles aren’t uniform things. History teaches us that under- and overvalued companies exist at almost all times.

Some of the companies covered in the Goldman report seem overvalued to me. Analysts, though, are frequently wrong.

We never know what a company is truly worth until its products are judged by consumers.

The Goldman report discusses Samumed, a private RM company. With $300 million in funding, it’s valued at a staggering $12 billion. Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.

As Samumed is not yet public, my interest in the company is academic. The larger question is what it means to more established RM companies.

AgeX Plans to Reverse Aging

The original RM company, Geron, is now folded into BioTime subsidiary Asterias. BioTime (*see disclosure below) is the core of my RM portfolio. This is largely because of Michael West, who pioneered the SCI therapy at Geron over 20 years ago.

To date, West's stem cell treatment for spinal cord injury is the most successful example of RM, but it’s 20 years old. Since that time, West’s research has progressed much further.

Last week, BioTime announced a new subsidiary, AgeX. AgeX has a range of stem cell IPs aimed at conditions such as cardiovascular repair and diabetes.

The true goals of AgeX, though, are much more radical. West intends to reverse aging … hence the company name.

He believes he can reactivate embryonic gene pathways to completely regenerate limbs and organs, including eyes, joints, and hearts. AgeX’s induced tissue regeneration technology would not only regenerate damaged and missing tissues.

It would turn back the biological clock of aging. West gave an excellent talk on this new science in his keynote address at the 2016 World Stem Cell Summit.

If he’s right, we’ll still have lots of problems, but the cost of age-related diseases won’t be one of them.

Stay in the Loop on Life-Extending Research with Patrick Cox's Tech Digest

This weekly newsletter by biotech expert Patrick Cox highlights research that is much more advanced than most people know, and the profit potential for investors is vast. Read about the latest breakthroughs—from new, non-invasive cancer treatments to age-reversing nutraceuticals and vaccines that kill any virus–as well as the innovative companies that work on them. Get Tech Digest free in your inbox every Monday.

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

John Mauldin Archive

© 2005-2018 - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.

Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules